Association between plasma CC16 levels, the A38G polymorphism, and asthma

被引:116
作者
Laing, IA
Hermans, C
Bernard, A
Burton, PR
Goldblatt, J
Le Souëf, PN
机构
[1] Univ Western Australia, Childrens Hosp, Med Ctr, Dept Paediat, Perth, WA 6001, Australia
[2] Univ Catholique Louvain, Unit Ind Toxicol & Occupat Med, Fac Med, B-1200 Brussels, Belgium
[3] TVW Telethon Inst Child Hlth Res, Div Biostat & Genet Epidemiol, W Perth, Australia
[4] Princess Margaret Hosp Children, Genet Serv, Perth, WA, Australia
关键词
D O I
10.1164/ajrccm.161.1.9904073
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The effect of the A38G polymorphism on Clara cell secretary protein (CC16) gene expression and asthma was investigated by measuring plasma CC16 levels in 100 asthmatic and nonasthmatic children. Restriction digestion determined the A38G genotype and plasma CC16 levels were analyzed using a sensitive latex immunoassay. Asthmatics had lower mean plasma CC16 levels adjusted for age and gender (7.96 mu g/L; 95% confidence interval [Cl] = 6.79 to 9.31) than nonasthmatic subjects (9.98 mu g/L; 95% CI = 8.83 to 11.26) (p = 0.006). Similarly adjusted, mean plasma CC16 levels were also lower in 38A/38A (6.79 mu g/L; 95% CI = 4.56 to 9.02) than 38G/38G subjects (10.01 mu g/L; 95% CI = 7.90 to 12.12; p = 0.003). The odds ratio for asthma diagnosis of 38A/38A subjects was 4.78 (95% CI = 1.08 to 21.18; p = 0.04) compared with 38G/38G subjects. However, this was reduced when corrected from plasma CC16 level suggesting that the odds of asthma was largely mediated through altered plasma CC16 levels. The 38A sequence was associated with reduced plasma CC16 levels and individuals with lower plasma CC16 levels were more likely to have asthma. This provides further evidence far a significant role of the CC16 gene, 38A allele in the development of asthma.
引用
收藏
页码:124 / 127
页数:4
相关论文
共 33 条
  • [1] ASTHMA FROM BIRTH TO AGE 23 - INCIDENCE AND RELATION TO PRIOR AND CONCURRENT ATOPIC DISEASE
    ANDERSON, HR
    POTTIER, AC
    STRACHAN, DP
    [J]. THORAX, 1992, 47 (07) : 537 - 542
  • [2] BALDINI M, 1998, AM J RESP CRIT CARE, V157, pA771
  • [3] BERNARD A, 1992, EUR RESPIR J, V5, P1231
  • [4] DETERMINATION BY LATEX IMMUNOASSAY OF PROTEIN-1 IN NORMAL AND PATHOLOGICAL URINE
    BERNARD, A
    LAUWERYS, R
    NOEL, A
    VANDELEENE, B
    LAMBERT, A
    [J]. CLINICA CHIMICA ACTA, 1991, 201 (03) : 231 - 245
  • [5] DETERMINATION OF CREATININE BY MEANS OF AUTOMATIC CHEMICAL ANALYSIS
    CHASSON, AL
    STANLEY, MA
    GRADY, HJ
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1961, 35 (01) : 83 - &
  • [6] DEHARO MSL, 1985, BIOCHEM J, V225, P255
  • [7] Dierynck I, 1996, Mult Scler, V1, P385
  • [8] Treatment of asthma with drugs modifying the leukotriene pathway
    Drazen, JM
    Israel, E
    O'Byrne, PM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (03) : 197 - 206
  • [9] Negative association between asthma and variants of CC16(CC10) on chromosome 11q13 in British and Japanese populations
    Gao, PS
    Mao, XQ
    Kawai, M
    Enomoto, T
    Sasaki, S
    Tanabe, O
    Yoshimura, K
    Shaldon, SR
    Dake, Y
    Kitano, H
    Coull, P
    Shirakawa, T
    Hopkin, JM
    [J]. HUMAN GENETICS, 1998, 103 (01) : 57 - 59
  • [10] Genetics and pulmonary medicine: asthma
    Hall, IP
    [J]. THORAX, 1999, 54 (01) : 65 - 69